ATAI Life Sciences (ATAI) said Thursday it was awarded a multi-year, milestone-driven grant worth up to $11.4 million by the National Institute on Drug Abuse, under the National Institutes of Health.
The grant will provide non-dilutive funding to advance Atai Life Sciences' 5-HT2A/2C receptor agonist program, which aims to develop novel compounds that will modulate serotonin receptors implicated in addiction, the company said.
Shares of the company were up nearly 3% in recent Thursday premarket activity.
精彩评论